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Background: The purpose of this study was to investigate the relationship between cognitive 
reserve and concentration of Aβ1-42 in the cerebrospinal fluid (CSF) of patients with mild 
cognitive impairment, those with Alzheimer’s disease, and in control subjects.
Methods: Thirty-three participants from the Argentina-Alzheimer’s Disease Neuroimaging 
Initiative database completed a cognitive battery, the Cognitive Reserve Questionnaire (CRQ), 
and an Argentinian accentuation reading test (TAP-BA) as a measure of premorbid intelligence, 
and underwent lumbar puncture for CSF biomarker quantification.
Results: The CRQ significantly correlated with TAP-BA, education, and Aβ1-42. When 
considering Aβ1-42 levels, significant differences were found in CRQ scores; higher levels of 
CSF Aβ1-42 were associated with higher CRQ scores.
Conclusion: Reduced Aβ1-42 in CSF is considered as evidence of amyloid deposition in 
the brain. Previous results suggest that individuals with higher education, higher occupational 
attainment, and participation in leisure activities (cognitive reserve) have a reduced risk of 
developing Alzheimer’s disease. Our results support the notion that enhanced neural activity 
has a protective role in mild cognitive impairment, as evidenced by higher CSF Aβ1-42 levels 
in individuals with more cognitive reserve.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
progressive functional and cognitive decline.1 Increasing evidence suggests that 
the pathological substrate of AD may begin years to decades before the clinical 
diagnosis, with an initial asymptomatic stage followed by a phase of mild cognitive 
impairment (MCI).
MCI is a nosological entity useful for identifying adults at risk of developing AD 
or other dementia syndromes. It is defined by objective evidence of cognitive impair-
ment, subjective memory complaints, and preserved global cognition and activities 
of daily living.2,3
Although rates of conversion from MCI to AD range from 5% to 23%, many indi-
viduals diagnosed with MCI remain stable or progress to a non-AD dementia.4
Hallmark lesions of sporadic AD comprise intraneuronal inclusions of abnormally 
phosphorylated tau protein and extracellular deposits of amyloid-beta peptide, espe-
cially the 42 amino acid isoform (Aβ1-42).
Cerebrospinal fluid (CSF) biomarkers, ie, Aβ1-42, phosphorylated tau181, and 
total tau, are altered in AD patients compared with controls: decreased Aβ1-42 reflects 
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deposition of amyloid-beta in plaques while high total tau 
levels reflect active axonal and neuronal damage.5–7
In other types of dementia, as well as in a subgroup of 
patients with MCI, less specific changes in these biomarker 
concentrations have been reported.8–10 Likewise, correlations 
between cognitive status and amyloid burden at autopsy have 
not been found. This fact raises the question about a possible 
relationship between cognitive status, amyloid burden, and 
disease progression.
On the other hand, many studies indicate that a set of life 
experiences, such as educational and occupational attain-
ment and leisure activities, is associated with reduced risk 
of developing dementia and with a slower rate of memory 
decline during normal aging. Several prospective studies 
reported that up to 25% of older subjects who were cogni-
tively normal in life met full pathological criteria for AD at 
autopsy.11,12 The cognitive reserve (CR) construct has been 
proposed to account for the discrepancy between the degree 
of brain pathology and its clinical manifestation. Therefore, 
individuals with high CR may tolerate substantial pathology 
before showing cognitive loss, whereas those with low CR 
may decline earlier. The CR paradigm postulates that indi-
vidual differences in cognitive achievement, and/or neural 
networks underlying task performance, allow some people 
to cope better than others with brain damage; according 
to the CR hypothesis, persons with higher CR can sustain 
cognitive function in the presence of more brain pathology 
than subjects with lower CR.13
Stimulating environments, a component of CR measured 
in humans by variables such as engagement in leisure activi-
ties and occupational attainment, promote neurogenesis in 
animals, and upregulate brain-derived neurotrophic factor, 
which fosters neural plasticity.14 There is evidence suggesting 
that environmental enrichment might act directly to prevent 
or slow the accumulation of AD pathology.15 Therefore, as 
cognitive stimulation regulates factors that increase neuronal 
plasticity, a complete account of CR should integrate the 
interactions between genetics, environmental influences on 
brain reserve, pathology, and the ability to actively compen-
sate for the effects of pathology.
Roe et al have investigated the relationship between 
CR, AD biomarkers, and the risk of cognitive impair-
ment, and found that Aβ1-42 combined with education 
and normalized whole brain-volume better predicts 
progression across follow-up.16 The purpose of this study 
was to investigate the relationship between CR and Aβ1-42 
con centrations.
Patients and methods
Patients
Thirty-three Caucasian participants from the Argentina 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data-
base (eight cognitively normal, 23 with amnesic MCI, two 
with AD; mean age 68.3±8.4 years, education 13.6±3.8 years 
and Mini Mental State Examination [MMSE] score 27.7±3.1) 
recruited at the Neurological Institute of Investigation 
between February and December 2013 were included for this 
investigation after giving their informed consent. The sub-
jects were included only if they agreed to undergo a lumbar 
puncture. Approval for the study was obtained from the ethics 
committee of the Neurological Institute of Investigation.
The diagnosis of MCI was established according to 
Petersen criteria, while the diagnosis of AD was done accord-
ing to the recommendations from the National Institute on 
Aging.3,17
Inclusion criteria were: age 55–90 years; written informed con-
sent obtained prior to the study; a Geriatric Depression Scale 
score 4; and education equivalent to 6 grade. Exclusion 
criteria included: medical history of psychiatric or any other 
neurological disease that could interfere with completion of 
assessments; consumption of psychoactive drugs; severe sen-
sory or comprehension deficit; and not consenting to lumbar 
puncture for CSF biomarkers.
Materials
During assessment, subjects completed the ADNI neuropsy-
chological battery, an Argentinian accentuation reading test 
(TAP-BA) that assesses the accentuation of 50 infrequent, 
irregularly stressed Spanish words as a measure of premorbid 
intelligence, and the Cognitive Reserve Questionnaire (CRQ) 
devised by Rami et al to estimate CR.18,19 They all underwent 
lumbar puncture to study CSF levels of total tau, phospho-
rylated tau181, and Aβ1-42. The research was conducted in 
accordance with the Declaration of Helsinki (1975).
CSF was collected by lumbar puncture at the L3/L4 or 
L4/L5 level during the morning. The first 20 drops were 
discarded and the remaining CSF (approximately 4–5 mL) 
was collected and aliquoted in polypropylene tubes. These 
tubes were stored at -80°C until analysis. Quantification of 
Aβ1-42, total tau, and phosphorylated tau181 was performed 
using commercially available enzyme-linked immunosorbent 
assay kits (Innogenetics, Ghent, Belgium) according to the 
manufacturer’s instructions. Briefly, 25 µL or 75 µL of CSF 
samples were used for measurement of Aβ1-42 and total tau or 
phosphorylated tau181, respectively. Samples were incubated 
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in the corresponding capture antibody-coated polypropylene 
plate with specific biotinylated monoclonal detector antibodies. 
After washing, the antigen-antibody complexes were detected 
by peroxidase-labeled streptavidin followed by addition of 
tetramethyl benzidine as the peroxidase substrate. Absorbance 
at 450 nm and 620 nm (used as reference wavelengths) was 
measured using a Benchmark Plus microplate spectrophotom-
eter (Bio-Rad, Hercules, CA, USA). Standard curve interpola-
tion of the data and subsequent analysis were performed using 
GraphPad Prism 5 software. Receiver operating characteristic 
analysis using a cohort of cognitively normal controls and AD 
patients showed that the cut-off point of 532.5 pg/mL best dis-
criminated these two populations (sensitivity 100%, specificity 
87.5%). MCI subjects were divided in two groups according to 
Aβ1-42 level (median 560 pg/mL; cut-off 532.5 pg/mL).
The ADNI is a large, multicenter, longitudinal neuroim-
aging study launched in 2004 by the National Institute on 
Aging, the National Institute of Biomedical Imaging and 
Bioengineering, the US Food and Drug Administration, 
private pharmaceutical companies, and nonprofit organiza-
tions. ADNI includes adult subjects aged 55–90 years who 
meet entry criteria for a clinical diagnosis of amnestic MCI, 
probable AD, or normal cognition. Participants receive 
baseline and periodic physical and neurological examina-
tions and standardized neuropsychological assessments, and 
provide biological samples (blood, urine, and in a subset, 
CSF) throughout the study. Imaging (magnetic resonance 
imaging and for a subset, F-fluorodeoxyglucose positron 
emission tomography [PET] and Pittsburgh compound B 
PET) is performed at baseline and at regular intervals there-
after (http://www.adni-info.org/).
The ADNI neuropsychological battery comprises the 
Spanish versions of: MMSE;20 Logical Memory;21 Clinical 
Dementia Rating;22 The Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (ADAS-Cog);23 Rey Auditory 
Verbal Learning Test (RAVLT);24 Montreal Cognitive 
Assessment (MoCA);25 Clock Drawing Test;26 Category 
fluency-animals;27 Trail Making Test A and B;28 and Boston 
Naming Test.29 Some of the tests selected for ADNI are:
•	 The MMSE, a 30-point questionnaire that is widely used 
to screen for cognitive impairment (10 points for spatial 
and temporal orientation; 6 points for memory retention 
and recall; 5 points for attention and calculation; 8 points 
for language; and 1 point for visual construction).
•	 The Boston Naming Test, a confrontation naming test that 
measures word retrieval using a set of pictures (30 items 
in the ADNI version).
•	 Story A from the WMS-III Logical Memory (subtest of 
the Wechsler Memory Scale) is an immediate and delay 
measure of episodic memory.
•	 The RAVLT, a list-learning paradigm in which the 
patient, after hearing a list of 15 nouns (list A) is asked 
to recall as many words from the list as possible (five 
repetitions of free-recall). An “interference” list (list B) is 
presented in the same manner, after the interference trial, 
the participant is immediately asked to recall the words 
from list A. After a 20-minute delay, the participant is 
asked to again recall the words from list A, followed by 
a recognition phase (50 words).
•	 The ADAS-Cog, a brief standardized test battery that 
assesses learning and memory, language production, lan-
guage comprehension, constructional praxis, ideational 
praxis, and orientation. Following the objective testing, 
subjective clinical ratings of language ability and the 
ability to remember test instructions are performed by 
the examiner.
•	 The Clinical Dementia Rating, a global measure of 
dementia, which is usually completed by a clinician by 
means of an interview with the patient and the caregiver 
(covered areas are memory, orientation, judgment and 
problem-solving, community affairs, home and hobbies, 
and personal care).
•	 Category fluency (animals), a widely used measure of 
semantic memory in which the subject is asked to name 
different exemplars from a given semantic category. 
The number of correct unique exemplars named is 
scored.
•	 The MoCA, designed as a rapid screening instrument 
for mild cognitive dysfunction, assesses attention and 
concentration, executive functions, memory, language, 
visuoconstructional skills, conceptual thinking, cal-
culations, and orientation. The total possible score is 
30 points; a score of 26 or above is considered normal.
•	 Trail Making Test, a test of processing speed and execu-
tive function. Although both Parts A and B depend on 
visual-motor and perceptual scanning skills, Part B also 
requires cognitive flexibility in shifting from number to 
letter sets under time pressure.
The CRQ included:
A) Education: (0–10)
•	 Patient years of education (0–5)
•	 Patient’s parents educational level (0–2)
•	 Patient training courses (0–3)
B) Working activity: (0–4)
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C) Leisure activity: (0–8)
•	 Musical training (0–2)
•	 Reading (0–4)
•	 Intellectual activities (0–2)
D) Languages (multilingualism): (0–3)
•	 Only mother tongue (first language; 0)
•	 Mother tongue plus a low fluency second language (1)
•	 Bilingualism (2)
•	 Multilingualism (3)
The total score is 25. The authors divided scores into 
quartiles to determine the level of CR (first quartile 6; sec-
ond quartile 7–9; third quartile 9–14; fourth quartile 15).
Data analysis
Analyses were performed using Statistical Package for the 
Social Sciences version 17.0 software. Association between 
variables (CSF biomarkers, CR, accentuation test, and neu-
ropsychological battery) was estimated using Spearman’s 
correlation coefficient. An independent-samples t-test was 
used for comparing groups according to AB1-42 or CR levels. 
Linear regression was performed to estimate the association 
between CRQ score and CSF Aβ1-42.
Results
There were no significant differences between the groups 
(control, MCI, AD) regarding sex, education, CRQ, or 
TAP-BA. The CRQ had a positive correlation with TAP-BA 
(rs=0.54; P0.005), education (rs=0.69; P0.001), and 
Aβ1-42 (rs=0.42; P0.05; Figure 1). Inverse correlations 
were found between CRQ and Trail Making Test A 
(rs=-0.54; P0.01) and Trail Making Test B (rs=-0.75; 
P0.001). Aβ1-42 significantly correlated with total 
tau (rs=-0.53; P0.005), Alzheimer’s profile (rs=0.79; 
P0.001) category fluency (animals; rs=0.45; P0.05), and 
RAVLT. Differences remained significant after correction 
for age. Significant correlations were found too between total 
tau and cognitive measures (category fluency and RAVLT). 
Sixteen subjects presented a positive Alzheimer’s profile 
(12 MCI, three controls, one AD). After dividing the MCI 
patients according to Aβ1-42 levels (cut-off 532.5 pg/mL), 
significant differences were found within subgroups in CRQ 
scores (P0.05; Table 1), showing that higher levels of CSF 
Aβ1-42, were associated with higher CRQ scores.
Significant differences were also found after classifying 
subjects according to their CR level (low, 15; high, 15); 
only four patients with high CR had CSF Aβ1-42 lower than 
the cut-off (Table 2). No other measure differed significantly 
across groups. No significant differences between MCI 
groups were found regarding age, education, and MMSE 
score (Table 2).
Discussion
Pathological hallmarks of AD include synaptic and neuronal 
degeneration and the presence of extracellular deposits of 
amyloid-beta in the cerebral cortex. With the advent of CSF 
biomarkers, such as tau and amyloid-beta (Aβ1-42), measur-
ing in vivo levels of peptides in CSF has been helpful for 
the diagnosis of AD.30 Some studies have reported that these 
markers could reflect brain pathology and could be used as 
surrogates for AD lesions.
Based on the CR theory, highly educated subjects 
would have more marked abnormalities in the CSF than 
those with a shorter education because of the compensatory 
effect over brain damage. Moreover, the CR hypothesis 
predicts that, at the same level of cognitive impairment, the 
Figure 1 correlation between cognitive reserve Questionnaire and aβ1-42 level. 
Abbreviation: crQ, cognitive reserve Questionnaire.
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Table 1 Demographic data
Normal MCI AD
n 8 23 2
education 14.71 (2.55) 13.88 (4.52) 15 (4.24)
age, years 60.75 (6.67) 65.88 (7.10) 81 (4.24)
sex (M/F) 4M/4F 11M/12F 2M
TaP-Ba 41.25 (8.32) 38.50 (8.57) 46 (2.83)
crQ 16 (2.24) 14.88 (4.99) 14 (2.83)
M31-42 861.15 (2.59) 684.71 (340.18) 704 (445.87)
MMse 29.14 (1.73) 28.75 (1.52) 19 (7.07)
Note: Data are expressed as the mean (standard deviation). 
Abbreviations: aD, alzheimer’s disease; Mci, mild cognitive impairment; 
crQ, cognitive reserve Questionnaire; MMse, Mini-Mental state examination; 
TaP-Ba, argentinian accentuation reading test.
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underlying pathology will be more advanced in individuals 
with higher CR.
According to Stern et al AD patients with higher educa-
tion exhibited a stronger brain pathology, including reduced 
temporoparietal PET with fluorodeoxyglucose or single 
photon emission computed tomography measurements, when 
compared with patients with AD with low educational attain-
ment at similar levels of dementia severity.31
The aim of the current investigation was to investigate 
the relationship between CR and concentrations of Aβ1-42 
in patients from our ADNI cohort. Several studies found an 
inverse correlation between Aβ1-42 and CR, suggesting that 
subjects with high CR have greater biomarker abnormalities 
than subjects with low CR. Similarly, Rolstad et al observed 
that, at the same level of clinical severity, patients converting to 
dementia with high CR had lower Aβ1-42 than converters with 
a medium and low CR (measured by educational level).32
On the other hand, recent studies proposed that amyloid-
beta secretion might be affected by neural activity and that 
enhanced lifestyle practices are associated with reduced 
amyloid-beta deposition (based on Pittsburgh compound B 
PET and CSF Aβ1-42).33–35
Jagust and Mormino observed that brain activity regulates 
amyloid-beta secretion and deposition.11 They hypothesize 
that CR may play different roles during pre-amyloid and 
post-amyloid plaque stages: once Aβ1-42 deposition begins, 
CR allows high CR individuals to cope better with neuronal 
dysfunction than in individuals with low CR. However, in 
pre-amyloid plaque stages, CR could act to diminish Aβ1-42 
production through better neural efficiency.
Our study revealed a significant direct relationship 
between CSF Aβ1-42 level and CRQ score. These results 
are consistent with the observation that participation in 
cognitively stimulating activities is associated with less 
accumulation of amyloid-beta.
Liang et al examined associations between exercise 
engagement and biomarker levels in older adults without 
clinical symptoms of AD, and observed that individuals 
with elevated Pittsburgh compound B PET, CSF tau or phos-
phorylated tau181, or decreased CSF Aβ1-42 consistently 
exercised less.36
The notion that cognitive activity influences the develop-
ment of AD pathology is supported by recent findings that 
cognitively normal older individuals with greater lifelong 
participation in complex mental activities showed less hip-
pocampal atrophy, another biomarker of AD pathology. These 
authors reported a direct association between cognitive activity 
and [11C] Pittsburgh compound B uptake, suggesting that life-
style factors found in individuals with high cognitive engage-
ment may prevent or slow deposition of Aβ1-42-amyloid.35
Bennet et al using crude counts of AD pathology from 
the maximally involved area from four 6 µm sections stained 
with modified Bielschowsky silver stains, reported that edu-
cation modified the relationship between senile plaques – but 
not neurofibrillary tangles – and level of cognition.37 Thus, 
focusing on amyloid-beta as the measure of primary AD 
pathology is based on previous studies showing that educa-
tion (cognitive reserve) reduced the impact of amyloid-beta 
pathology but not tau pathology on cognitive performance.
This preliminary result supports the hypothesis of the 
protective role of enhanced lifelong neural activity on amy-
loid deposition and the utility of biomarkers, specifically 
Aβ1-42, as substitutes for pathology in relation to CR. To our 
knowledge, this preliminary study is the first Argentinian 
investigation reporting this association. A prospective analysis 
of cognitive decline in a larger cohort would be important in 
order to determine the frequency of conversion from MCI to 
dementia. The limitations of this paper include the small size of 
the sample due to the inclusion criterion requiring that patients 
from the ADNI protocol consent to a lumbar puncture.
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